. Author manuscript; available in PMC: 2013 Feb 19.

Published in final edited form as: Ophthalmology. 2008 Jul;115(7):1109–1116.e7. doi: 10.1016/j.ophtha.2008.03.033

Table 7.

Synopses of Prior Studies

Study	Synopsis
Gedde et al 2007a⁸	Seventeen clinical centers studied 212 patients aged 18–85 with previous trabeculectomy and/or cataract surgery, and persistently high intraocular pressure despite maximum medical therapy were randomized to either trabeculectomy or implantation of a 350 mm² Baerveldt GDD. Glaucoma studied: POAG, CACG, PXFG, PG, other. Mean follow-up: 54–60 months.
Al-Torbak et al 2007¹³	All patients implanted with Ahmed Valve GDDs between January 1994 and November 2003 were screened for endophthalmitis in a relational database of all surgeries performed at King Khaled Eye Specialist Hospital in Riyadh, Saudi Arabia. Age ranged from 0.8–78 years. Glaucoma studied: congenital, secondary, primary. Median follow-up: 8.9 months.
Wilson et al 2003¹⁴	One hundred twenty-three consecutive patients needing surgical treatment for POAG or CACG, with no previous intraocular surgery or conditions requiring combined surgeries at Columbo Eye Hospital in Sri Lanka were randomized to receive either trabeculectomy or an Ahmed implant. Glaucoma studied: POAG, CACG. Mean follow-up: 31 months.
Tong et al 2003¹⁵	Researchers reviewed medical records of all (19) patients undergoing 2-stage implantation of Baerveldt GDD for advanced glaucoma between January 1995 and November 1998 at Doheny Eye Institute who had a minimum of 6 months follow up or whose surgery failed within 6 months. Patients were aged 30–88 years. Glaucoma studied: angle closure glaucoma, combined mechanism, open angle glaucoma, uveitic. Median follow-up: 17 months.
Roy et al 2002¹⁶	Medical records were reviewed for 48 patients with medically uncontrolled refractory glaucoma, no longer eligible for filtering surgery, who underwent Baerveldt implant surgery between June 1994 and December 1998, and were followedup for a minimum of 12 months at Jules Gonin Hospital, Lausanne, Switzerland. Mean (SD) age of patients was 58.4 (21.6) years. Glaucoma studied: traumatic, aphakic, neovascular, uveitic, congenital. Mean follow-up: 37.6 months.
Krishna et al 2001¹⁷	Data on all patients at Bascom Palmer Eye Institute from January 1989 to August 1998 receiving Baerveldt 350-mm² implants and no concurrent trabeculectomy or revision of trabeculectomy or implant, who had a minimum of 2 years of follow-up or implant failure within 2 years (n = 4) were extracted from medical records. Glaucoma studied: POAG, neovascular, uveitic, other. Follow-up: 24 months.
Wilson et al 2000¹⁸	One hundred seventeen patients aged >4 years from 1 hospital in Saudi Arabia and 1 in Sri Lanka were randomized to trabeculectomy or implantation of an Ahmed GDD for glaucoma. Mean (SD) age for the GDD group was 52.63 (2.51), and for the trabeculectomy group, 51.76 (2.18). Glaucoma studied: POAG, CACG, secondary. Mean follow-up: 9.7 months.
Britt et al 1999¹⁹	Medical records of 107 patients randomly assigned to 350/500-mm Baerveldt devices at Doheny Eye Institute between March 1999 and April 1993 were reviewed. Results presented are for those participants available for follow-up at 2–5 years, aged >12 years, with no diagnosis of neovascular glaucoma or uveitis, no record of previous cyclodestructive procedures, and who met additional restrictions. Glaucoma studied: aphakic, anterior chamber of intraocular lens, posterior chamber intraocular lens. Mean follow-up: 37 and 34 months.

CACG = chronic angle closure glaucoma; GDD = glaucoma drainage device; PG = primary glaucoma; POAG = primary open-angle glaucoma; PXFG = Pseudoexfoliation glaucoma; SD = standard deviation.